Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Jiang J, Zhao C, Zhang F, et al. ALK inhibitors in ALK-rearranged non-small cell lung cancer with and without brain metastases: systematic review and network meta-analysis. BMJ Open 2022;12:e060782. doi:10.1136/bmjopen-2022-060782
This article has been corrected since it was published online. In the discussion section, the first sentence in first paragraph has been changed from “Throughout the recent randomised clinical trials relating second-generation inhibitors, the median PFS with alectinib in the ALEX Study (34.8 months) was significantly improved,35 followed by ensartinib in the eXalt3 Study (25.8 months),33 and brigatinib in the ALTA-1L Study (24.0 months)” to “Throughout the recent randomized clinical trials relating second-generation inhibitors, the median PFS (independent committee) times were 25.7 months with alectinib of ALEX study, 25.8 months with ensartinib of eXalt3 study, and 24.0 months with brigatinib of ALTA-1L study”.